Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Editas Medicine (EDIT)
Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 627,864
  • Shares Outstanding, K 68,996
  • Annual Sales, $ 19,710 K
  • Annual Income, $ -220,430 K
  • 60-Month Beta 1.86
  • Price/Sales 31.78
  • Price/Cash Flow N/A
  • Price/Book 1.97
Trade EDIT with:

Options Overview Details

View History
  • Implied Volatility 81.22% ( +6.46%)
  • Historical Volatility 66.01%
  • IV Percentile 33%
  • IV Rank 46.57%
  • IV High 126.47% on 07/27/22
  • IV Low 41.78% on 05/24/23
  • Put/Call Vol Ratio 0.47
  • Today's Volume 1,383
  • Volume Avg (30-Day) 1,984
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 32,594
  • Open Int (30-Day) 37,126

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.77
  • Number of Estimates 10
  • High Estimate -0.56
  • Low Estimate -0.93
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +1.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.69 +18.34%
on 05/02/23
10.71 -15.03%
on 05/10/23
+1.20 (+15.19%)
since 04/26/23
3-Month
6.33 +43.76%
on 04/12/23
10.71 -15.03%
on 05/10/23
+0.04 (+0.44%)
since 02/24/23
52-Week
6.33 +43.76%
on 04/12/23
19.97 -54.43%
on 08/08/22
-1.76 (-16.21%)
since 05/26/22

Most Recent Stories

More News
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?

It's facing a few issues that are practically guaranteed to affect shareholder returns.

BLUE : 3.56 (+2.30%)
EDIT : 9.10 (+0.22%)
CRSP : 64.66 (+1.27%)
PFE : 37.60 (-0.61%)
BEAM : 32.37 (+0.50%)
ARKK : 39.10 (+1.88%)
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus....

BMY : 63.82 (-1.15%)
ADMA : 4.08 (+3.55%)
EDIT : 9.10 (+0.22%)
APTX : 0.0714 (-0.83%)
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 9.10 (+0.22%)
BFRI : 0.4648 (-1.11%)
Editas: Q1 Earnings Snapshot

Editas: Q1 Earnings Snapshot

EDIT : 9.10 (+0.22%)
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDXS : 2.47 (-0.40%)
EDIT : 9.10 (+0.22%)
Earnings Preview: Editas Medicine (EDIT) Q1 Earnings Expected to Decline

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EDIT : 9.10 (+0.22%)
Why Shares of Editas Medicine Rose Monday

The company is benefiting from positive news affecting other gene-editing stocks.

EDIT : 9.10 (+0.22%)
CRSP : 64.66 (+1.27%)
VRTX : 329.99 (-0.79%)
2 Stocks Under $15 Per Share to Consider

Anyone can get in on the stock market at these prices.

EDIT : 9.10 (+0.22%)
SNAP : 10.28 (+5.11%)
Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

EDIT : 9.10 (+0.22%)
ARGX : 401.96 (+0.22%)
Proceed With Caution When Considering These 5 Ultra-Popular Stocks

Four of these five stocks are losing money.

AMC : 4.64 (-1.28%)
SNDL : 1.5600 (-0.32%)
NFLX : 378.88 (+5.54%)
EDIT : 9.10 (+0.22%)
TLRY : 1.8600 (-21.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 9.50
2nd Resistance Point 9.36
1st Resistance Point 9.23
Last Price 9.10
1st Support Level 8.95
2nd Support Level 8.81
3rd Support Level 8.68

See More

52-Week High 19.97
Fibonacci 61.8% 14.76
Fibonacci 50% 13.15
Fibonacci 38.2% 11.54
Last Price 9.10
52-Week Low 6.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar